HealthDay News — For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large cell lymphoma (BIA-ALCL), according to a ...

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory ...